Persistent rheumatoid arthritis symptoms may be driven by factors beyond mere joint inflammation, according to researchers at Semmelweis University. Sleep disorders, depression, smoking, and obesity can help keep symptoms active, challenging the traditional view that inflammation alone dictates disease severity in difficult-to-treat cases.
Researchers examining difficult-to-treat rheumatoid arthritis have found that lifestyle factors and co-occurring health conditions do more than simply accompany the chronic autoimmune disease. Published across Nature Reviews Rheumatology and The Lancet Rheumatology, the findings show that conditions like depression, smoking, and sleep problems actively contribute to persistent pain and fatigue.
The Vicious Cycle of Pain, Mood, and Sleep
Rheumatoid arthritis is a chronic autoimmune disease where the immune system mistakenly attacks the joints, causing pain, swelling, and stiffness. In Hungary alone, it affects tens of thousands of people. While most patients respond well to standard treatments, roughly 6 to 28 percent fall into a difficult-to-treat category because they fail to achieve lasting remission.
The Semmelweis University team reports that secondary conditions create a self-reinforcing loop. Pain and depression reduce physical activity, which can lead to weight gain and further deteriorate sleep quality and mood. These compounding changes then intensify pain, making daily activities more difficult for patients.
Did you know? Between 6 and 28 percent of rheumatoid arthritis patients fail to achieve lasting remission, landing them in the difficult-to-treat category despite ongoing therapy.
Using Current Clinical Frameworks as Early Warning Systems
To address these complex cases, the researchers introduced a new model that adapts the widely used “treat-to-target” approach. Traditionally, doctors regularly track measurable indicators of disease activity and escalate medication doses or switch drugs if inflammation fails to drop.
The Semmelweis team argues this framework can double as an early warning system. If measurable inflammation markers improve but a patient continues reporting pain and fatigue, doctors should consider whether other factors are driving the symptoms rather than automatically increasing drug dosages.
“When target values improve but the patient still suffers from pain and fatigue, it is worth taking a step back. In such cases, instead of automatically prescribing more medication, doctors should look for what is maintaining the symptoms – whether it is chronic pain syndrome, depression, sleep disorders, or obesity,” said Dr. György Nagy, head of the Department of Rheumatology and Immunology at Semmelweis University.
International Reach and Artificial Intelligence Integration
The team’s conceptual framework has achieved substantial international traction. Publications introducing the difficult-to-treat disease concept and its corresponding management strategy have accumulated more than a thousand citations from other researchers worldwide. The definition is now applied broadly across other diseases beyond rheumatoid arthritis.
Looking ahead, the research group is turning toward digital health innovations. Alongside ongoing clinical studies, the team plans to participate in projects using artificial intelligence to refine care strategies.
“With AI-based pattern recognition, we could identify subgroups among patients, and with the help of these data we could create more effective, almost personalized treatment strategies for them,” explained Dr. Lilla Gunkl-Tóth, a PhD student at Semmelweis University and first author of the publications.
Frequently Asked Questions
What makes rheumatoid arthritis difficult to treat?
Patients fall into the difficult-to-treat category when they do not achieve lasting remission despite standard therapy, often due to overlapping health issues like sleep disorders, obesity, and depression.
How does the new Semmelweis University model change patient care?
The model uses standard treat-to-target indicators as an early warning system, prompting doctors to investigate non-inflammatory drivers—such as chronic pain syndrome or mood disorders—when inflammation drops but symptoms persist.
What role does artificial intelligence play in future treatments?
Researchers plan to use AI-based pattern recognition to identify distinct patient subgroups and develop personalized treatment strategies based on comprehensive health data.
Take Action: Want to stay informed on the latest breakthroughs in rheumatology and clinical research? Subscribe to our newsletter or explore our archive for more in-depth reporting.
Related reading